ERBB2 and triple-negative breast carcinoma: Exploratory post-hoc subgroup analyses revealed that survival was reduced in the local therapy arm of 20 participants with triple-negative breast cancer (HR, 3.33; 95% CI, 1.09–10.12) but similar among those with other subtypes (HR, 1.05; 95% CI, 0.49–2.24 for human epidermal growth factor receptor 2 [HER2]-positive; HR, 0.88; 95% CI, 0.56–1.39 for hormone-receptor-positive HER2-negative).